The South and Central America systemic aspergillosis and systemic candidasis market is projected to reach US$ 395.06 million by 2027 from US$ 308.09 million in 2019; it is estimated to grow at a CAGR of 3.2% from 2020 to 2027. The market growth is primarily attributed to rise in the prevalence of fungal diseases and hospital-acquired fungal infections. Moreover, the COVID-19 pandemic has highly affected countries in South and Central America, further affecting the systemic aspergillosis and systemic candidiasis market in the region.
Fungal systemic infections are common in patients with weakened immune system, including people suffering from acquired immunodeficiency syndrome (AIDS). Systemic signs include indications such as apnea, guaiac-positive stools, abdominal distension, hyperglycemia, leukemoid reaction, and hypotension. Systemic aspergillosis and systemic candidasis are the types of fungal infections. Molds cause aspergillosis infections and majorly affect the respiratory tract of individuals. Aspergillus is a common fungus that affects people with weakened immune systems or lung diseases, and the fungus Candida auris is a cause of severe global health threats. People facing other health problems, including AIDS, asthma, cancer, organ transplantation, and corticosteroid therapies may acquire severe fungal infections. These infections can be treated with parenteral antifungal therapy. Early accurate diagnosis allows prompt antifungal treatment; however, the treatments are often delayed or are unavailable, leading to death, severe chronic illness, or blindness. These conditions may result in permanent neurodevelopmental deficits in long-term survivors; they are also associated with high mortality rates. According to a study published in the Journal of Fungi, in March 2017, HIV/AIDS pandemic, tuberculosis, chronic obstructive pulmonary disease (COPD), and asthma, and the increasing incidence of various cancer types are the primary drivers of fungal infections in both developed and developing countries in the world. Furthermore, as per a study published by the National Center for Biotechnology Information, in December 2017, the burden of asthma with fungal sensitization in the 43 countries considered for the study is ~599,283, with an estimated rate of ~288/100,000 of population. Thus, the rising prevalence of fungal infections is driving the South and Central America systemic aspergillosis and systemic candidasis market.
In 2019, the systemic oral azoles accounted for the highest share and is expected to grow faster during the forecast period as due to its advancementin systemic antifungal therapy. For instance, fluconazole has the most attractive pharmacologic (pharmacokinetics and pharmacodynamic) profile, including the capacity to produce high concentrations of active drug in cerebrospinal fluid and urine.
A few of the major primary and secondary sources associated with this report on the South and Central America systemic aspergillosis and systemic candidasis market are the US Food and Drug Administration (FDA), National Library of Medicine – National Institutes of Health, and International Society for Human and Animal Mycology.